Targeting the Mitochondrial Unfolded Protein Response in Prostate Cancer

Dhyan ChandraDr. Dhyan Chandra, Roswell Park Comprehensive Cancer Center, USA will join us this year to present his most recent findings on "Targeting the Mitochondrial Unfolded Protein Response in Prostate Cancer".

Dr. Dhyan Chandra has identified the mitochondrial unfolded protein response (UPRmt) as a new target for prostate cancer treatment and management. His research team revealed that the two key components of the UPRmt, heat shock protein 60 (HSP60, a mitochondrial chaperonin) and caseinolytic protease (ClpP, a mitochondrial protease) work together and are required for the development of advanced prostate cancer. They observed that HSP60 acts as upstream regulator of ClpP expression and HSP60 interacts with ClpP to maintain mitochondrial function.

Dr. Chandra has also discovered a novel UPRmt (referred to as DCEM1) that inhibits HSP60 interactions with ClpP in prostate cancer cells and prostate tumors, leading to the blockade prostate cancer growth and progression in preclinical study. Since the current androgen deprivation and taxane-based therapy are not effective, these findings provide alternative treatment approaches for prostate cancer that do not rely on androgen receptor signaling axis.      

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers like Dr. Chandra. Book your spot.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 

Mitochondria in the Press & Media

  • 1
  • 2
Prev Next


News archive